Asset Details
Do you wish to reserve the book?
Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?
Do you wish to request the book?
Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?
2020
Overview
Cough is an important symptom of asthma. The objective assessment of chronic cough has been enhanced by the development of ambulatory cough monitoring systems. Mepolizumab has been demonstrated to reduce exacerbations in eosinophilic asthmatics long-term. We evaluate the utility of objective cough count as an outcome measure in severe eosinophilic asthma treated with mepolizumab. Consecutive, consenting patients initiated on treatment with mepolizumab had a 24-h cough count recorded at baseline; this was repeated at 1, 3 and 6 months. Asthma control questionnaire (ACQ) scores and exacerbation frequency were also recorded. The mean 24-h cough count in 11 subjects (8 females, mean age 53.6 years) was 172.4 at baseline; at 1, 3 and 6 months following initiation of treatment this decreased to 101.4, 92 and 70.8, respectively (
p
< 0.02). Significant improvements were also observed in mean ACQ score (3–1.6,
p
< 0.01) and exacerbation frequency (5.5 per year – 1.3,
p
< 0.01). Objective cough measurement could be used as an early, precise and clinically relevant endpoint in assessing response to asthma therapy.
Publisher
Springer US,Springer,Springer Nature B.V
